title: Sufficiency of Single-Arm Studies to Support Registration of Targeted Agents in Molecularly Selected Patients with Cancer: Lessons from the Clinical Development of Crizotinib.
authors: Pfizer Oncology, La Jolla, California, USA.
authors: P
authors: P
authors: Selaru
authors: Pfizer Oncology, La Jolla, California, USA.
authors: Y
authors: Y
authors: Tang
authors: Pfizer Oncology, Groton, Connecticut, USA.
authors: B
authors: B
authors: Huang
authors: Pfizer Oncology, Milan, Italy.
authors: A
authors: A
authors: Polli
authors: Pfizer Oncology, La Jolla, California, USA.
authors: K D
authors: KD
authors: Wilner
authors: Pfizer Oncology, Cambridge, Massachusetts, USA.
authors: E
authors: E
authors: Donnelly
authors: Pfizer Oncology, La Jolla, California, USA.
authors: D P
authors: DP
authors: Cohen
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D000077547:Crizotinib; D017277:Drug Approval; D055808:Drug Discovery; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics; D011720:Pyrazoles / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D011720:Pyrazoles; D011725:Pyridines; D000077547:Crizotinib